vs
QuidelOrtho Corp（QDEL）与罗致恒富（RHI）财务数据对比。点击上方公司名可切换其他公司
罗致恒富的季度营收约是QuidelOrtho Corp的1.9倍（$1.3B vs $699.9M），QuidelOrtho Corp同比增速更快（-3.7% vs -5.8%），罗致恒富自由现金流更多（$170.8M vs $-94.7M），过去两年QuidelOrtho Corp的营收复合增速更高（-2.9% vs -6.1%）
奎德尔奥索公司是美国的诊断医疗产品制造商，旗下产品面向全球市场销售，深耕体外诊断领域，为医疗机构及相关用户提供专业的检测解决方案，助力全球医疗健康服务效率提升。
罗致恒富是1948年成立的国际人力资源咨询机构，总部位于加利福尼亚州门洛帕克和圣拉蒙，是全球规模领先的会计与金融领域人才派遣服务商之一，在全球范围内设有超过345个办公点。
QDEL vs RHI — 直观对比
营收规模更大
RHI
是对方的1.9倍
$699.9M
营收增速更快
QDEL
高出2.0%
-5.8%
自由现金流更多
RHI
多$265.5M
$-94.7M
两年增速更快
QDEL
近两年复合增速
-6.1%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $699.9M | $1.3B |
| 净利润 | $-733.0M | — |
| 毛利率 | — | 37.6% |
| 营业利润率 | -100.7% | 1.7% |
| 净利率 | -104.7% | — |
| 营收同比 | -3.7% | -5.8% |
| 净利润同比 | -3583.4% | — |
| 每股收益（稀释后） | $-10.78 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收QDELRHI
| Q4 25 | — | $1.3B | ||
| Q3 25 | $699.9M | $1.4B | ||
| Q2 25 | $613.9M | $1.4B | ||
| Q1 25 | $692.8M | $1.4B | ||
| Q4 24 | $707.8M | $1.4B | ||
| Q3 24 | $727.1M | $1.5B | ||
| Q2 24 | $637.0M | $1.5B | ||
| Q1 24 | $711.0M | $1.5B |
净利润QDELRHI
| Q4 25 | — | — | ||
| Q3 25 | $-733.0M | $42.9M | ||
| Q2 25 | $-255.4M | $41.0M | ||
| Q1 25 | $-12.7M | $17.4M | ||
| Q4 24 | $-178.4M | — | ||
| Q3 24 | $-19.9M | $65.5M | ||
| Q2 24 | $-147.7M | $68.2M | ||
| Q1 24 | $-1.7B | $63.7M |
毛利率QDELRHI
| Q4 25 | — | 37.6% | ||
| Q3 25 | — | 37.2% | ||
| Q2 25 | — | 37.2% | ||
| Q1 25 | — | 36.9% | ||
| Q4 24 | — | 38.8% | ||
| Q3 24 | — | 39.0% | ||
| Q2 24 | — | 39.2% | ||
| Q1 24 | — | 38.1% |
营业利润率QDELRHI
| Q4 25 | — | 1.7% | ||
| Q3 25 | -100.7% | 1.0% | ||
| Q2 25 | -29.4% | 0.1% | ||
| Q1 25 | 4.7% | 2.9% | ||
| Q4 24 | -14.2% | 4.7% | ||
| Q3 24 | 2.1% | 4.1% | ||
| Q2 24 | -18.4% | 5.1% | ||
| Q1 24 | -247.3% | 2.8% |
净利率QDELRHI
| Q4 25 | — | — | ||
| Q3 25 | -104.7% | 3.2% | ||
| Q2 25 | -41.6% | 3.0% | ||
| Q1 25 | -1.8% | 1.3% | ||
| Q4 24 | -25.2% | — | ||
| Q3 24 | -2.7% | 4.5% | ||
| Q2 24 | -23.2% | 4.6% | ||
| Q1 24 | -239.9% | 4.3% |
每股收益（稀释后）QDELRHI
| Q4 25 | — | $0.32 | ||
| Q3 25 | $-10.78 | $0.43 | ||
| Q2 25 | $-3.77 | $0.41 | ||
| Q1 25 | $-0.19 | $0.17 | ||
| Q4 24 | $-2.54 | $0.53 | ||
| Q3 24 | $-0.30 | $0.64 | ||
| Q2 24 | $-2.20 | $0.66 | ||
| Q1 24 | $-25.50 | $0.61 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $98.1M | $464.4M |
| 总债务越低越好 | $2.5B | — |
| 股东权益账面价值 | $2.0B | $1.3B |
| 总资产 | $5.7B | $2.9B |
| 负债/权益比越低杠杆越低 | 1.23× | — |
8季度趋势，按日历期对齐
现金及短期投资QDELRHI
| Q4 25 | — | $464.4M | ||
| Q3 25 | $98.1M | $365.3M | ||
| Q2 25 | $151.7M | $380.5M | ||
| Q1 25 | $127.1M | $342.5M | ||
| Q4 24 | $98.3M | $537.6M | ||
| Q3 24 | $143.7M | $570.5M | ||
| Q2 24 | $107.0M | $547.4M | ||
| Q1 24 | $78.5M | $540.9M |
总债务QDELRHI
| Q4 25 | — | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.1B | — | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $2.2B | — | ||
| Q1 24 | $2.2B | — |
股东权益QDELRHI
| Q4 25 | — | $1.3B | ||
| Q3 25 | $2.0B | $1.3B | ||
| Q2 25 | $2.8B | $1.3B | ||
| Q1 25 | $3.0B | $1.3B | ||
| Q4 24 | $3.0B | $1.4B | ||
| Q3 24 | $3.2B | $1.5B | ||
| Q2 24 | $3.2B | $1.5B | ||
| Q1 24 | $3.3B | $1.5B |
总资产QDELRHI
| Q4 25 | — | $2.9B | ||
| Q3 25 | $5.7B | $2.8B | ||
| Q2 25 | $6.4B | $2.8B | ||
| Q1 25 | $6.5B | $2.7B | ||
| Q4 24 | $6.4B | $2.9B | ||
| Q3 24 | $6.8B | $3.0B | ||
| Q2 24 | $6.7B | $2.9B | ||
| Q1 24 | $6.7B | $2.9B |
负债/权益比QDELRHI
| Q4 25 | — | — | ||
| Q3 25 | 1.23× | — | ||
| Q2 25 | 0.74× | — | ||
| Q1 25 | 0.70× | — | ||
| Q4 24 | 0.72× | — | ||
| Q3 24 | 0.68× | — | ||
| Q2 24 | 0.70× | — | ||
| Q1 24 | 0.68× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-45.5M | $182.5M |
| 自由现金流经营现金流 - 资本支出 | $-94.7M | $170.8M |
| 自由现金流率自由现金流/营收 | -13.5% | 13.1% |
| 资本支出强度资本支出/营收 | 7.0% | 0.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-153.1M | $266.8M |
8季度趋势，按日历期对齐
经营现金流QDELRHI
| Q4 25 | — | $182.5M | ||
| Q3 25 | $-45.5M | $77.4M | ||
| Q2 25 | $-46.8M | $119.4M | ||
| Q1 25 | $65.6M | $-59.3M | ||
| Q4 24 | $63.7M | $154.8M | ||
| Q3 24 | $117.9M | $129.6M | ||
| Q2 24 | $-97.9M | $142.0M | ||
| Q1 24 | $-700.0K | $-15.9M |
自由现金流QDELRHI
| Q4 25 | — | $170.8M | ||
| Q3 25 | $-94.7M | $63.6M | ||
| Q2 25 | $-84.3M | $104.2M | ||
| Q1 25 | $9.4M | $-71.7M | ||
| Q4 24 | $16.5M | $140.5M | ||
| Q3 24 | $71.4M | $111.8M | ||
| Q2 24 | $-133.2M | $129.6M | ||
| Q1 24 | $-66.8M | $-27.7M |
自由现金流率QDELRHI
| Q4 25 | — | 13.1% | ||
| Q3 25 | -13.5% | 4.7% | ||
| Q2 25 | -13.7% | 7.6% | ||
| Q1 25 | 1.4% | -5.3% | ||
| Q4 24 | 2.3% | 10.2% | ||
| Q3 24 | 9.8% | 7.6% | ||
| Q2 24 | -20.9% | 8.8% | ||
| Q1 24 | -9.4% | -1.9% |
资本支出强度QDELRHI
| Q4 25 | — | 0.9% | ||
| Q3 25 | 7.0% | 1.0% | ||
| Q2 25 | 6.1% | 1.1% | ||
| Q1 25 | 8.1% | 0.9% | ||
| Q4 24 | 6.7% | 1.0% | ||
| Q3 24 | 6.4% | 1.2% | ||
| Q2 24 | 5.5% | 0.8% | ||
| Q1 24 | 9.3% | 0.8% |
现金转化率QDELRHI
| Q4 25 | — | — | ||
| Q3 25 | — | 1.80× | ||
| Q2 25 | — | 2.91× | ||
| Q1 25 | — | -3.42× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 2.08× | ||
| Q1 24 | — | -0.25× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
RHI
| Finance And Accounting | $535.2M | 41% |
| Protiviti | $479.0M | 37% |
| Technology | $156.4M | 12% |
| Permanent Placement Talent Solutions | $102.6M | 8% |
| Other | $29.2M | 2% |
